• Modern approaches to the treatment of cough

Modern approaches to the treatment of cough

SOVREMENNAYA PEDIATRIYA.2017.7(87):47-52

Bentsa T. M.
Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

Cough takes an important place among the symptoms conditioned by respiratory organ pathology. Mucoactive agents have been the medications of choice for the treatment of respiratory diseases in which mucus hypersecretion is a clinical complication. The main purpose of mucoactive drugs is to increase the ability to expectorate sputum and/or decrease mucus hypersecretion. Mucoactive medications include expectorants, mucoregulators, mucolytics and mucokinetics. Mechanisms of mucolytic, antioxydative and antitoxic effects of acetylcysteine on respiratory organs are considered. The drug is high effective fot treatment of different inflammatory diseases of respiratory tract with increase of bronchial secretion viscosity. The drug can modify the rheological properties of the tracheobronchial secretion reducing its viscosity and accelerating the discharge processes from the bronchial tract, which results in a more rapid recovery of the patient. The article presents the data about indications, contraindications and peculiarities of treatment with acetylcysteine.

Key words: cough, treatment, mucolytics, acetylcysteine.

References            

1. Ivashev M.N., Sergienko A.V. (2013). Klinicheskaya farmakologiya atsetiltsisteina. Uspehi sovremennogo estestvoznaniya. 5: 116—117.

2. Klyachkina I.L., Sinopalnikov A.I. (2013). Mukoaktivnyie preparatyi. Ratsionalnaya farmakoterapiya zabolevaniy organov dyihaniya. Rukovodstvo dlya praktikuyuschih vrachey. Pod obsch. red. A.G. Chuchalina. 2-e izd. Moskva: Literra: 103—117.

3. Mukoaktivnaya terapiya. (2006). Pod. red. A.G. Chuchalina, A.S. Belevskogo. Moskva: Atmosfera: 127.

4. Mukovistsidoz. Sovremennyie dostizheniya i aktualnyie problemyi. Metodicheskie rekomendatsii. (2011). Pod. red. N.I. Kapranova, N.Yu. Kashirskoy. Moskva: MGNTs: 124.

5. Sinopalnikov A.I., Klyachkina I.L. (2013). Kashel. Moskva: MIA: 168.

6. Chuchalin A.G., Abrosimov V.N. (2012). Kashel. Moskva: Eho: 128.

7. Andersen LW, Thiis J, Kharazmi A. (1995). The role of N-acetylcystеin administracion on the oxidative response of neutrophils during cardiopulmonагу bypass. Perfusion. 10(1): 21—26.

8. Balsamo R, Lanata L, Egan CG. (2010). Mucoactive drugs. Eur Respir Rev. 19(116): 127—133.

9. Barnes PJ, Adcock IM, Ito K. (2005). Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J. 25(3): 552—563.

10. Bennet PN, Brown MJ. (2008). Clinical Pharmacology. 10th ed: 132. https://doi.org/10.1111/j.1365-2125.2007.03041.x; PMid:17922880 PMCid:PMC2291373

11. Decramer M, Rutton-van Molken M, Dekhujzen PN et al. (2005). Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (BRONCUS): a randomized placebo-controlled trial. Lancet. 365(9470): 1552—1560.

12. Morice AH, Fontana GA, Belvisi MG et al. (2007). ERS Task Force. ERS quidelines on the assessment of cough. Eur Respir J. 29: 1256—1276.

13. Zuin R, Palamidese A, Negrin R et al. (2005). High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig. 25(6): 401—408.

14. Kardos P. (2010). Management of cough in adults. Breathe. 7(2): 123—133.

15. Louis R. (2017). How to approach a chronic cough. Rev Med Liege. 72(2): 106—110.

16. Millea PJ. (2009). AT-Acetylcysteine: multiple clinical applications. Am Fam Physician. 80(3): 265—269.

17. Cacciatore I, Cornacchia C, Pinnen F et al. (2010). Prodrug approach for increasing cellular glutathione levels (review). Molecules. 15: 1242—1264.

18. Morice A, McGarvey L, Pavord I et al. (2006). Recommendations for the management of cough in adults. Thorax. 61; Suppl 1: 1—24.

19. Rogers DF. (2007). Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 52(9): 1176—1193.

20. Sheffner AI. (1963). The reduction in vitro in viscosity of mucoprotein solution by a new mucolytic agent, N-acetylcysteine. Ann NY Acad Sci. 106: 298-310.

21. Aruoma OI, Halliwell B, Ноеy BM et al. (1989). The antioxidaпt action of N-acetylcysteine: its reaction with hydrogen peroxide, hvdroxyl radical, superoxide and hypochlorous acid. Free Radic Biol Med. 6(6): 593—597.

22. Fowdar K, Chen H, He Z et al. (2017). The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: a meta-analysis and systematic review. Heart Lung. 46(2): 120—128.

23. Zheng CH, Ahmed K, Rikicomi N et al. (1999). The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol. 43(2): 107—113.

24. Satia I, Badri H, Al-Sheklly B et al. (2016). Towards understanding and managing chronic cough. Clin Med. 16; Suppl 6: 92—97.

25. Tse HN, Tseng CZ. (2014). Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 6(9): 825—836.